• In the past week, Cardinal Health prepared to report earnings alongside other major companies, while markets also monitored key US labor data and a pending Federal Reserve leadership nomination.
• Attention on Cardinal Health has increased as its role in the healthcare supply chain and expectations for higher revenue highlight its negotiating strength in a tightly regulated market.
• Next, we will examine how anticipation of Cardinal Health’s upcoming earnings and healthcare supply chain demand shapes its broader investment narrative.

We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

What Is Cardinal Health's Investment Narrative?

For someone considering Cardinal Health today, the big picture is believing in the durability of its role at the center of the healthcare supply chain, even as the stock already reflects strong recent returns and a relatively rich earnings multiple. The upcoming Q2 2026 earnings release, set against expectations for higher revenue and double‑digit earnings growth, is the near term catalyst that could either justify that premium or invite a reset. The latest macro headlines, including the proposed Kevin Warsh Fed nomination and closely watched labor data, may influence market sentiment, but they are unlikely to change the fundamentals driving drug distribution volumes or hospital demand in the short run. Instead, the more immediate swing factors remain pricing pressure, high debt levels, and Cardinal’s ability to keep translating its scale into resilient margins.

However, investors should not ignore how Cardinal’s high debt load could amplify any earnings disappointment. Cardinal Health's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Four Simply Wall St Community fair value estimates for Cardinal Health span roughly US$168 to US$468, showing how far apart private investors can be. Set against the company’s upcoming earnings catalyst and elevated valuation, this spread underlines why you may want to review different scenarios for how Cardinal’s negotiating power and debt profile could affect future performance.

Explore 4 other fair value estimates on Cardinal Health - why the stock might be worth 23% less than the current price!

Build Your Own Cardinal Health Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Cardinal Health research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Cardinal Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cardinal Health's overall financial health at a glance.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.